Context Therapeutics Inc. · NASDAQ:CNTX
Context Therapeutics — Investor Presentation (January 2022)
22 slides from Context Therapeutics's investor presentation, Jan 10, 2022
Slide 1: Bringing Change for Female Cancers
Corporate Presentation January 2022 BRINGING CHANGE FOR FEMALE CANCERS
Slide 2: Forward Looking Statement
Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that m
Slide 3: Company Highlights: Executive Summary
Company Highlights Nasdaq: CNTX3 Executive Summary Focus on Women’s Oncology → Unmet clinical need in breast, ovarian, and endometrial cancers Lead Asset: ONA-XR oral PR antagonist → Progesterone receptor (PR) oncogenic signaling is associated with breast, ovarian, and endometrial cancer1 → Onaprist
Slide 4: Pipeline
Nasdaq: CNTX4 Pipeline Executive Summary (1) Tyligand Biosciences Ltd licensed rights to ONA-XR in China, HK, Macau Cancer Clinical Indication Research Phase 1 Phase 2 Phase 3 Upcoming Milestones FDA Fast Track ONA-XR (PR antagonist)1 Breast Cancer 1L ER+,PR+,HER2- ctDNAhigh • Phase 1b data Mid 2022
Slide 5: Market Opportunity: Prevalence of Metastatic Female Hormone-Driven Cancers
89,000 28,000 25,000 104,000 30,000 28,000 35,000 12,000 11,000 - 50,000 100,000 150,000 200,000 250,000 Breast Cancer Ovarian Cancer Endometrial Cancer P at ie nt s US EU5 JP2 Nasdaq: CNTX5 Executive Summary *Source: secondary epidemiologic estimates, 2020 estimates Market Opportunity Prevalence of
Slide 6: Experienced Team
Nasdaq: CNTX6 Executive Summary Experienced Team • We believe that clinical development of ONA-XR is primarily a function of exacting clinical execution • Our CMO led the clinical development of multiple blockbuster drugs for female cancers, including Kisqali, Arimidex, and Afinitor • Our management
Slide 7: Lead Asset ONA-XR Progesterone Receptor Antagonist
Lead Asset ONA-XR Progesterone Receptor Antagonist 7 Nasdaq: CNTX
Slide 8: Onapristone Extended Release (ONA-XR)
Onapristone Extended Release (ONA-XR) Nasdaq: CNTX8 ONA-XR Mechanism of Action → Onapristone is a progesterone receptor (PR) antagonist that suppresses PR oncogenic signaling → PR oncogenic signaling is associated with breast, ovarian, and endometrial cancer → Onapristone is the only known clinical-
Slide 9: Clinical Development Strategy
Clinical Development Strategy Blocking cancer growth by combining antiestrogen and antiprogestin therapies Nasdaq: CNTX9 ONA-XR Proliferation Immune System Suppression Stemness DNA DamageCell Survival Estrogen Progesterone Cancer Driver Stimulus Cancer Growth and MetastasisOutcome
Slide 10: ONA-XR Evaluation in Breast Cancer Trials
ONA-XR Evaluation in Breast Cancer Trials 10 Nasdaq: CNTX Treatment Line Context Trial Clinical Collaborator Trial Status Estimated Patients (US)4 Standard of Care (SOC) Medical Need Adjuvant (after primary disease treatment) Window of Opportunity1 Completed >>250,000 Antiestrogen Enhance antiestrog
Slide 11: ONA-XR Evaluation in Gynecologic Trials
ONA-XR Evaluation in Gynecologic Trials 11 Nasdaq: CNTX Cancer Context Trial Clinical Collaborator Trial Status Estimated Patients (US)3 Standard of Care (SOC) Medical Need Recurrent Endometrial Combination with Anastrozole in PR+ patients1 Enrolling Patients 25,000 Lenvima + Keytruda Limited treatm
Slide 12: ONA-XR ONAWA (SOLTI-1802) Preliminary Data
ONA-XR ONAWA (SOLTI-1802) Preliminary Data Nasdaq: CNTX12
Slide 13: Window of Opportunity Trial in Primary Breast Cancer
Window of Opportunity Trial in Primary Breast Cancer Nasdaq: CNTX13 ONAWA (SOLTI-1802) Preliminary Data Bellet et al., San Antonio Breast Cancer Symposium 2021 Key Eligibility Criteria • Post-menopausal women • Histologically confirmed invasive breast carcinoma • PR+, ER+, HER2- as per local assessm
Slide 14: High PR Expression Associated with Treatment Response
High PR Expression Associated with Treatment Response ONAWA (SOLTI-1802) Preliminary Data Nasdaq: CNTX14 ONA-XR treatment response was seen in the high PR patient population Post-ONA-XR reduction in cell proliferation marker Ki67 = marker of cell proliferation Bellet et al., San Antonio Breast Cance
Slide 15: ONA-XR Shifted Tumors to a More Hormone-sensitive State
ONA-XR Shifted Tumors to a More Hormone-sensitive State A post-treatment switch to a more hormone-sensitive phenotype was observed, as shown by the increase Luminal A score at surgery (post-3 weeks of ONA-RX) and risk of recurrence (ROR) scores Nasdaq: CNTX15 ONAWA (SOLTI-1802) Preliminary Data The
Slide 16: Claudin Program
Claudin 6 Program 16 Nasdaq: CNTX
Slide 17: CLDN6 x CD3 Bispecific Antibody Program
CLDN6 x CD3 Bispecific Antibody Program Nasdaq: CNTX17 Claudin 6 Tumor cell T cell CD3CLDN6 Cytotoxic cytokines Lysis CLDN6 x CD3 bispecific antibody Claudin-6 is a tumor-specific protein in adults Integrating Claudin-6 binding with the CD3 T-cell engager couples immunotherapy to tumor specific targ
Slide 18: Competitive Landscape/Advantage
Competitive Landscape/Advantage • Based on internal studies and published data, Context anti- CLDN6 binding is at least 10x more selective vs. CLDN9 than competitive anti-CLDN6 mAbs and bispecifics • CLDN6:CLDN9 binding selectivity is a critical safety factor for CLDN6- targeted bispecific antibodie
Slide 19: Corporate
Corporate 19 Nasdaq: CNTX
Slide 20: Upcoming Milestones
Upcoming Milestones ONA-XR Q4 2021 1H 2022 2H 2022 Breast – Window of Opportunity data presentation Breast – mechanism of action data presentation Breast – 1L (ctDNA enriched) Phase 1b trial update Endometrial – Phase 2 trial update Breast – 2L/3L (post-CDK4/6) Phase 2 trial update Granulosa Cell –
Slide 21: Corporate Investment Highlights
Nasdaq: CNTX21 Corporate Investment Highlights Female Cancers Large Unmet Need Progesterone Receptor and Claudin 6 High Value Targets Multiple Data Readouts in 2022 Near-Term Milestones Deep Domain Experience, Track Record of Success Strong Team Expected cash runway into 2024 Financial Strength
Slide 22: Bringing Change for Female Cancers
BRINGING CHANGE FOR FEMALE CANCERS © CONTEXT THERAPEUTICS 2022
Context Therapeutics — Investor Presentation (January 2022) on 6ix